Brainstorm Cell Therapeutics Inc Market Cap ($11.73 Million)
Market Cap & Net Worth: Brainstorm Cell Therapeutics Inc (BCLI)
Brainstorm Cell Therapeutics Inc market cap. Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) has a market capitalization of $11.73 Million ($11.73 Million) as of November 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26539 globally and #5547 in its home market, demonstrating a -0.68% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Brainstorm Cell Therapeutics Inc's stock price $1.06 by its total outstanding shares 11034775 (11.03 Million). Also see Brainstorm Cell Therapeutics Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Brainstorm Cell Therapeutics Inc Market Cap History (2015–2026)
Brainstorm Cell Therapeutics Inc market cap history from 2015 to 2026. Data shows change from $473.39 Million to $11.73 Million (-28.56% CAGR). Check today's stock price for Brainstorm Cell Therapeutics Inc for real-time trading data and today's change.
Index Memberships
Brainstorm Cell Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #740 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #2424 of 3165 |
Weight: Brainstorm Cell Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Brainstorm Cell Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Brainstorm Cell Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Brainstorm Cell Therapeutics Inc growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
8.68x
Brainstorm Cell Therapeutics Inc's market cap is 8.68 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $708.43 Million | $-366.00K | -$23.25 Million | -1935.61x | N/A |
| 2024 | $25.05 Million | $849.00K | $11.62 Million | 29.50x | 2.16x |
| 2025 | $6.10 Million | $703.00K | -$10.31 Million | 8.68x | N/A |
Competitor Companies of BCLI by Market Capitalization
Companies near Brainstorm Cell Therapeutics Inc in the global market cap rankings as of November 2, 2026. Also see BCLI total asset value for a full breakdown of the balance sheet.
Key companies related to Brainstorm Cell Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Brainstorm Cell Therapeutics Inc (2015–2026)
Market capitalization of Brainstorm Cell Therapeutics Inc from 2015 to today. Between 2015 and today, Brainstorm Cell Therapeutics Inc's market cap moved from $473.39 Million to $ 11.73 Million, with a yearly change of -28.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $11.73 Million | +92.17% |
| 2025 | $6.10 Million | -75.64% |
| 2024 | $25.05 Million | -44.57% |
| 2023 | $45.19 Million | -83.35% |
| 2022 | $271.46 Million | -59.00% |
| 2021 | $662.09 Million | -11.60% |
| 2020 | $748.99 Million | +5.72% |
| 2019 | $708.43 Million | +20.56% |
| 2018 | $587.60 Million | -9.44% |
| 2017 | $648.84 Million | +54.33% |
| 2016 | $420.42 Million | -11.19% |
| 2015 | $473.39 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 1st, 2026 the market cap of Brainstorm Cell Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.73 Million USD |
| MoneyControl | $11.73 Million USD |
| MarketWatch | $11.73 Million USD |
| marketcap.company | $11.73 Million USD |
| Reuters | $11.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Brainstorm Cell Therapeutics Inc
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modul… Read more